Summary
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ledford, H., Else, H. & Warren, M. Cancer immunologists scoop medicine Nobel prize. Nature 562, 20–21 (2018).
Kaumaya, P. T. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol. 16, 1767–1791 (2020).
Foy, K. C., Liu, Z., Phillips, G., Miller, M. & Kaumaya, P. T. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J. Biol. Chem. 286, 13626–13637 (2011).
Miller, M. J., Foy, K. C., Overholser, J. P., Nahta, R. & Kaumaya, P. T. P. HER-3 peptide vaccines/mimics: combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology 3, e956012 (2014).
Foy, K. C., Miller, M. J., Overholser, J., Donnelly, S. M., Nahta, R. & Kaumaya, P. T. P. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology 3, e956005 (2014).
Bekaii-Saab, T., Wesolowski, R., Ahn, D. H., Wu, C., Mortazavi, A., Lustberg, M. et al. Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and nor-MDP adjuvant in patients with advanced solid tumors. Clin. Cancer Res. 25, 3495–3507 (2019).
Kaumaya, P. T. P., Guo, L., Overholser, J., Penichet, M. L. & Bekaii-Saab, T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 9, 1818437 (2020).
Acknowledgements
Not applicable.
Author information
Authors and Affiliations
Contributions
L.G. wrote the first draft. P.K. edited the manuscript, wrote the revised version and drafted the figure. Both authors approved this manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent to publish
Not applicable.
Data availability
All the data relevant to this manuscript are included in the article or in our previous publications (see refs. 6,7). Other data information’s available on reasonable request from the corresponding author.
Competing interests
P.T.P.K. is co-inventor on patents regarding PD1-Vaxx which has licensed such patents from OSU to Imugene Ltd. P.T.P.K. has partial inventor rights to PD1-Vaxx which has been licensed for commercial development. P.T.P.K. is consultant to Imugene Ltd. L.G. declares no competing interests. No writing assistance was utilised in the production of this manuscript.
Funding information
Funded by National Institutes of Health NIH CA84356, NIH R21CA13508 and Imugene Ltd to P.T.P. Kaumaya.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guo, L., Kaumaya, P.T.P. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. Br J Cancer 125, 152–154 (2021). https://doi.org/10.1038/s41416-021-01342-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01342-9